Authors
Vishal Kumar, Honey Modi, Loise Råberg, Leila D Rostami, Jessica M Rosenholm, Carl-Eric Wilén, Alexandra Stubelius, Rohit Goyal, Kuldeep K Bansal
Published in
International journal of pharmaceutics. Pages 127472. Sep 28, 2026. Epub Sep 28, 2026.
Abstract
Lumiracoxib (LXB) was in use for the treatment of rheumatoid arthritis and osteoarthritis but was withdrawn from the market due to severe hepatotoxicity. Nevertheless, nanotechnology-based reformulation of such drug can tailor pharmacokinetics through controlled release and reduced off-target liver accumulation, improving efficacy and safety. Thus, the present study explored the potential of poly(δ-decalactone) (PDL)-based nanoemulsion (NE) to reduce the hepatic toxicity of LXB. Tailor-made diblock (mPEG-b-PDL) and triblock (PDL-b-PEG-b-PDL) co-polymers were used as surfactants, while homopolymers (B-PDL, B-PJL-COOH and B-PJL-OH) were used as polymeric oil to fabricate NEs. NEs prepared using B-PDL (F3 and F4) enhanced the aqueous solubility of LXB by 30.4 ± 5.4 and 37.3 ± 4.8-fold, respectively. In vitro cytotoxicity results revealed that prepared NEs reduced the cytotoxicity of LXB in liver cancer (HepG2) cells by approx. 2-fold. Furthermore, liver toxicity and inflammatory markers were evaluated using Multiplex® after LXB NE treatment and results showed that NEs performed better compared to free LXB. Evaluation in an in vivo arthritic model further demonstrated NEs capability in reducing LXB-induced hepatic toxicity with improved anti-inflammatory activity. These findings suggest that PDL NEs may offer a promising strategy for improving the biopharmaceutical performance and safety profile of LXB.
PMID:
42805575
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0